The first-line oral agent for type 2 diabetes mellitus is metformin. Metformin's primary mechanism of action is the inhibition of hepatic gluconeogenesis. It also increases peripheral glucose uptake and insulin sensitivity, but its main effect is on the liver. The other options describe different classes of antidiabetic drugs: sulfonylureas (B), thiazolidinediones (C), and SGLT2 inhibitors (D).

Weight gain and fluid retention leading to peripheral edema are characteristic side effects of thiazolidinediones (TZDs), such as pioglitazone and rosiglitazone. These drugs act as agonists for the peroxisome proliferator-activated receptor-gamma (PPAR-γ), a nuclear receptor that increases insulin sensitivity in adipose tissue, muscle, and liver. Fluid retention is a major concern, especially in patients with heart failure.

Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. These drugs block glucose reabsorption in the proximal renal tubule, leading to glucosuria. The increased glucose in the urine creates a favorable environment for microbial growth, significantly increasing the risk of urinary tract infections and vulvovaginal candidiasis. Lactic acidosis is associated with metformin (B). Agranulocytosis is a rare side effect of thionamides (C). Pancreatitis is a concern with GLP-1 agonists and DPP-4 inhibitors (D).

In primary hypothyroidism, the thyroid gland fails, leading to low T4 and a compensatory increase in TSH from the pituitary. Levothyroxine is synthetic T4. Treatment replaces the deficient hormone, increasing free T4 levels. The increased T4 provides negative feedback to the pituitary, which suppresses TSH secretion, bringing it back down into the normal range. Therefore, successful treatment is marked by a decrease in TSH and an increase in free T4.

Methimazole is a thionamide drug that inhibits thyroid peroxidase (TPO). TPO is the key enzyme in thyroid hormone synthesis, responsible for oxidizing iodide to iodine and then incorporating it into tyrosine residues on thyroglobulin (organification). By blocking TPO, methimazole effectively halts the synthesis of new thyroid hormone. It does not block the peripheral conversion of T4 to T3 (B), a property unique to PTU. Iodide uptake (C) is blocked by perchlorate. Release of preformed hormone (D) is inhibited by high doses of iodine.

Glucocorticoids, such as prednisone, are well-known to cause hyperglycemia. They do so by multiple mechanisms: they stimulate hepatic gluconeogenesis and glycogenolysis, and they decrease peripheral glucose uptake and utilization by muscle and adipose tissue, creating a state of insulin resistance. Autoimmune destruction of beta cells (B) is the cause of type 1 diabetes. Glucocorticoids increase glucagon secretion (C) and decrease, rather than enhance, peripheral glucose uptake (D).

Prolonged use of exogenous glucocorticoids (e.g., prednisone for >3 weeks) suppresses the HPA axis through negative feedback on the hypothalamus (CRH) and pituitary (ACTH). This leads to adrenal cortex atrophy. Abrupt cessation of the steroid unmasks this suppression, resulting in an iatrogenic acute adrenal insufficiency (adrenal crisis) because the atrophied adrenal glands cannot produce enough endogenous cortisol to meet physiologic demands.

Spironolactone is a potassium-sparing diuretic that acts as a competitive antagonist of the mineralocorticoid (aldosterone) receptor. However, its structure is similar to sex hormones, and it is non-selective, also acting as an antagonist at androgen receptors and an agonist at progesterone receptors. Its antiandrogenic effects can cause gynecomastia, decreased libido, and impotence in men, and its progestogenic effects can cause breast tenderness and menstrual irregularities in women.

The patient has central diabetes insipidus, characterized by a deficiency of antidiuretic hormone (ADH, or vasopressin). Desmopressin (DDAVP) is a synthetic analog of ADH with high selectivity for the V2 receptor and minimal activity at the V1a receptor. Activation of V2 receptors in the principal cells of the renal collecting ducts stimulates the insertion of aquaporin-2 water channels into the apical membrane, increasing water reabsorption and concentrating the urine.

Alendronate is a bisphosphonate. Bisphosphonates are pyrophosphate analogs that bind to hydroxyapatite in bone. They are taken up by osteoclasts during bone resorption. Inside the osteoclast, they inhibit farnesyl pyrophosphate synthase, disrupting a key metabolic pathway and inducing osteoclast apoptosis. This reduces bone resorption, allowing osteoblastic activity to predominate, thereby increasing bone mineral density. The specific administration instructions are to prevent esophagitis, a major side effect.